Viral vectors are the preferred choice for the development of gene therapies, with adeno-associated viruses (AAV), and lentiviruses (LV) being the most adopted systems. Given the increased demand, viral-vector manufacturing requires rapid expansion and standardization across the industry. Diverse manufacturing modalities raise concerns about regulatory standards and quality control, particularly regarding raw materials. Supplementation of recombinant insulin to chemically defined media is vital to support viral-vector production in mammalian cells, enhancing the titers of AAV and LV in HEK293 cells.
Where can I learn more?
For more information visit our case study about the effects of insulin on viral vectors production in HEK293 cells.
